PriceTargets.com logo

Curaleaf - CURLF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.25
  • Forecasted Upside: 181.53%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$2.22 As of 11/15/2024 01:00 AM ET
▲ +0.02 (0.91%)

This chart shows the closing price for CURLF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Curaleaf Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CURLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CURLF

Analyst Price Target is $6.25
▲ +181.53% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Curaleaf in the last 3 months. The average price target is $6.25, with a high forecast of $6.25 and a low forecast of $6.25. The average price target represents a 181.53% upside from the last price of $2.22.

This chart shows the closing price for CURLF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Curaleaf. This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/10/2024Roth CapitalUpgradeStrong-Buy
11/7/2024CormarkDowngradeModerate Buy ➝ Hold
8/12/2024CormarkUpgradeHold ➝ Moderate Buy
8/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$6.25 ➝ $6.25
5/10/2024Needham & Company LLCBoost TargetBuy ➝ Buy$5.25 ➝ $6.25
3/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$4.25 ➝ $5.25
8/11/2023Stifel NicolausLower TargetC$3.50 ➝ C$3.00
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$4.25
7/31/2023Stifel NicolausDowngradeBuy ➝ Sell
7/5/2023ATB CapitalInitiated CoverageOutperform
7/4/2023Atb Cap MarketsReiterated RatingOutperform
5/19/2023BenchmarkDowngradeBuy ➝ Hold
4/14/2023WedbushReiterated RatingOutperform$8.50
4/14/2023Alliance Global PartnersLower TargetBuy$11.00 ➝ $8.00
2/8/2023Stifel NicolausLower TargetC$8.50 ➝ C$8.00
1/25/2023Atb Cap MarketsReiterated RatingOutperform
12/30/2022Cantor FitzgeraldLower TargetOverweight$13.00 ➝ $12.00
12/1/2022WedbushInitiated CoverageOutperform$8.50
11/8/2022Stifel NicolausLower TargetC$9.50 ➝ C$8.50
11/8/2022Cantor FitzgeraldLower TargetOverweight$13.50 ➝ $13.00
10/31/2022Seaport Res PtnReiterated RatingBuy
10/28/2022Cantor FitzgeraldLower TargetOverweight$13.70 ➝ $13.50
10/28/2022BTIG ResearchReiterated RatingBuy
10/26/2022Roth CapitalReiterated RatingBuy
8/9/2022Canaccord Genuity GroupLower TargetC$14.50 ➝ C$13.50
8/9/2022Alliance Global PartnersLower TargetC$15.00 ➝ C$12.00
8/9/2022CowenLower Target$25.00 ➝ $10.00
5/10/2022Canaccord Genuity GroupLower TargetC$15.50 ➝ C$14.50
5/10/2022Stifel NicolausLower TargetC$25.00 ➝ C$24.00
5/10/2022MKM PartnersReiterated RatingBuy$14.00
4/25/2022Cantor FitzgeraldBoost TargetOverweight$15.50 ➝ $16.50
3/7/2022Stifel NicolausLower TargetC$31.00 ➝ C$25.00
3/4/2022Cantor FitzgeraldLower TargetOverweight$16.50 ➝ $15.50
3/4/2022Needham & Company LLCLower TargetBuy$17.00 ➝ $15.00
2/25/2022BenchmarkInitiated CoverageBuy$12.00
1/7/2022Wolfe ResearchInitiated CoveragePeer Perform
1/4/2022Cantor FitzgeraldLower TargetOverweight$18.50 ➝ $16.50
11/9/2021Roth CapitalLower TargetBuy$19.00 ➝ $16.00
11/9/2021Stifel NicolausLower TargetBuyC$33.00 ➝ C$31.00
11/9/2021Alliance Global PartnersLower TargetBuyC$29.00 ➝ C$23.00
11/9/2021Craig HallumDowngradeBuy ➝ Hold
11/8/2021Craig HallumLower TargetAverage ➝ Buy$21.00 ➝ $16.00
11/3/2021Cantor FitzgeraldLower TargetOverweight$24.00 ➝ $20.00
11/1/2021Stifel NicolausBoost TargetBuyC$32.25 ➝ C$33.00
10/8/2021Needham & Company LLCLower TargetBuy$19.75 ➝ $19.00
8/10/2021Needham & Company LLCInitiated CoverageBuy$19.75
8/3/2021Needham & Company LLCReiterated RatingBuy$19.75
7/7/2021Jefferies Financial GroupInitiated CoverageBuy$32.00
3/10/2021Cantor FitzgeraldBoost TargetOverweight$23.50 ➝ $26.50
3/10/2021Needham & Company LLCBoost TargetBuy$18.50 ➝ $19.75
3/8/2021BTIG ResearchInitiated CoverageBuy
2/25/2021Stifel NicolausBoost TargetBuy$23.00 ➝ $32.25
1/20/2021Roth CapitalBoost TargetBuy$14.00 ➝ $20.00
1/20/2021Cantor FitzgeraldBoost TargetOverweight$20.00 ➝ $23.50
1/19/2021Needham & Company LLCBoost TargetBuy$14.00 ➝ $18.50
12/3/2020Craig HallumInitiated CoverageBuy$19.00
11/18/2020Needham & Company LLCBoost TargetBuy$13.50 ➝ $14.00
11/18/2020Cantor FitzgeraldBoost TargetOverweight$18.00 ➝ $20.00
8/18/2020Alliance Global PartnersBoost TargetBuy$14.00 ➝ $16.00
8/18/2020Needham & Company LLCBoost TargetBuy$11.00 ➝ $13.50
8/18/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$18.00
8/6/2020Needham & Company LLCBoost TargetBuy$10.70 ➝ $11.00
8/4/2020Cantor FitzgeraldBoost TargetNeutral$7.50 ➝ $10.00
7/23/2020Alliance Global PartnersBoost TargetBuy$12.00 ➝ $14.00
7/22/2020Stifel NicolausInitiated CoverageBuy
6/22/2020Needham & Company LLCReiterated RatingBuy$10.70
6/8/2020Roth CapitalInitiated CoverageBuy$9.00
5/19/2020Cantor FitzgeraldBoost TargetNeutral$6.00 ➝ $7.50
5/19/2020Needham & Company LLCBoost TargetBuy$5.90 ➝ $10.10
5/12/2020Needham & Company LLCBoost TargetBuy$5.50 ➝ $5.90
3/25/2020Cantor FitzgeraldBoost TargetNeutral$4.10 ➝ $4.70
3/17/2020Needham & Company LLCLower TargetBuy$8.80 ➝ $5.50
2/13/2020Cantor FitzgeraldInitiated CoverageNeutral$8.60
2/11/2020Alliance Global PartnersInitiated CoverageBuy
12/23/2019Needham & Company LLCReiterated RatingBuy$7.25
12/3/2019Needham & Company LLCInitiated CoverageBuy$7.25
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 13 very positive mentions
  • 17 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 5 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 6 very positive mentions
  • 13 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 6 very positive mentions
  • 13 positive mentions
  • 7 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Curaleaf logo
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
Read More

Today's Range

Now: $2.22
Low: $2.06
High: $2.25

50 Day Range

MA: $2.89
Low: $1.66
High: $3.55

52 Week Range

Now: $2.22
Low: $1.64
High: $6.40

Volume

731,740 shs

Average Volume

715,814 shs

Market Capitalization

$1.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Curaleaf?

The following equities research analysts have issued research reports on Curaleaf in the last year: Cormark, Needham & Company LLC, and Roth Capital.
View the latest analyst ratings for CURLF.

What is the current price target for Curaleaf?

0 Wall Street analysts have set twelve-month price targets for Curaleaf in the last year. Their average twelve-month price target is $6.25, suggesting a possible upside of 181.5%. Needham & Company LLC has the highest price target set, predicting CURLF will reach $6.25 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $6.25 for Curaleaf in the next year.
View the latest price targets for CURLF.

What is the current consensus analyst rating for Curaleaf?

Curaleaf currently has 1 hold rating, 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CURLF will outperform the market and that investors should add to their positions of Curaleaf.
View the latest ratings for CURLF.

What other companies compete with Curaleaf?

Other companies that are similar to Curaleaf include ADMA Biologics, TG Therapeutics, Biohaven, Crinetics Pharmaceuticals and BridgeBio Pharma. Learn More about companies similar to Curaleaf.

How do I contact Curaleaf's investor relations team?

Curaleaf's physical mailing address is 301 Edgewater Place, Wakefield, MA 01880. The company's listed phone number is 781-451-0351 and its investor relations email address is [email protected]. The official website for Curaleaf is www.curaleaf.com. Learn More about contacing Curaleaf investor relations.